Artificial Intelligence Based Melanoma Early Diagnosis and Risk Prediction in Children, Adolescents and Young Adults

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorGerman Cancer Research Center

About this trial

The goal of this study is to develop supportive diagnostic artificial intelligence algorithms to distinguish melanoma from nevi or other benign pigmented skin lesions, especially in younger patients (below the age of 30). The main goals it aims to achieve are:

* development of an algorithm based on dermatoscopic images, targeting skin cancer screening in vulnerable populations * development of another algorithm based on histological images, intended to be used by pathologists on lesions that are still suspicious of melanoma after dermatologic assessment * implementation of explainability methods to enable the user to better comprehend the systems' decisions, avoid biases and increase trust in these applications

There is no additional time commitment for the study participants for this study, as the data used in this project will be collected in routine clinical practice anyway.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

None

Disqualifiers

Patients without a melanoma or nevus diagnosis

images with insufficient image quality

Trial population

Mainly children (up to and including 15 years of age), adolescents (16-20) and young adults (from 21 to 30 years of age)

Trial design

Design model

Case-only

Time perspective

Other

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Area Under the Receiver Operator Curve (AUROC)

The AUROC is used to measure and compare the diagnostic accuracy of different classifiers. Thereby, a higher value means better diagnostic performance, with an AUROC of 1 being a perfect score.

Time frame
First Assessment: Upon completion of the first training and testing cycle (approx. within 1.5 years from the start of the study). Reevaluations: at 6 and 12 months post-initial training for model improvement.

Secondary outcomes

1

Balanced accuracy

The balanced accuracy is used to measure and compare the diagnostic accuracy between classifier and physician. Thereby, a higher value means better diagnostic performance, with a balanced accuracy of 1 signifying perfect diagnostic capabilities.

Time frame
First Assessment: Upon completion of the first training and testing cycle (approx. within 1.5 years from the start of the study). Reevaluations: at 6 and 12 months post-initial training for model improvement.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

German Cancer Research Center

Lead sponsor

Universität Tübingen

Collaborator

University of Florence

Collaborator

Fundacio Clinic Barcelona

Collaborator

Hospital Clinic of Barcelona

Collaborator